Ọkpụkpụ obi na mbelata ejection fraction (HFrEF) bụ isi ụdị nkụda mmụọ, na China HF Nnyocha gosiri na 42% nke nkụda mmụọ obi na China bụ HFrEF, n'agbanyeghị na ọtụtụ ọkọlọtọ ọgwụgwọ klas dị maka HFrEF ma belata ihe ize ndụ. nke ọnwụ na ụlọ ọgwụ maka ọdịda obi ruo n'ókè ụfọdụ.Otú ọ dị, ndị ọrịa nọ n'ihe ize ndụ nke ịda mbà n'obi na-emeghachi omume na-akawanye njọ, ọnwụ na-anọgide na gburugburu 25% na prognosis na-anọgide na-adịghị mma.Ya mere, a ka nwere mkpa ngwa ngwa maka ndị na-ahụ maka ọgwụgwọ ọhụrụ na ọgwụgwọ HFrEF, na Vericiguat, ihe na-akpali akpali guanylate cyclase (sGC), nke a mụrụ na VICTORIA ọmụmụ iji chọpụta ma Vericiguat nwere ike imeziwanye prognosis nke ndị ọrịa nwere HFrEF.Ọmụmụ ihe a bụ multicenter, randomized, parallel-group, placebo-controlled, double-kpuru, ihe omume na-eduzi, usoro nke atọ na-arụpụta ụlọ ọgwụ.Emere n'okpuru nkwado nke VIGOR Center na Canada na mmekorita ya na Duke Clinical Research Institute, ụlọ ọrụ 616 na mba 42 na mpaghara, gụnyere Europe, Japan, China na United States, sonyere na ọmụmụ ihe ahụ.A kwanyere ngalaba mmụta gbasara obi anyị ugwu isonye.Ngụkọta nke ndị ọrịa 5,050 na-arịa ọrịa obi na-adịghị ala ala nke afọ ≥18 afọ, NYHA klas II-IV, EF <45%, na elu natriuretic peptide (NT-proBNP) ọkwa n'ime 30 ụbọchị tupu randomization, na onye nọ n'ụlọ ọgwụ maka nkụda mmụọ obi. n'ime ọnwa 6 tupu ịgbanye ma ọ bụ nwee diuretics a na-enye n'ime intravenously maka obi mgbawa n'ime ọnwa 3 tupu randomization edebanye aha na ọmụmụ ihe ahụ, ndị niile na-anata ESC, AHA / ACC, na ntụziaka mba / mpaghara kwadoro ụkpụrụ nlekọta.A na-ekewa ndị ọrịa na nha 1: 1 na otu abụọ ma nye yaVericiguat(n=2526) na placebo (n=2524) n'elu usoro ọgwụgwọ ọkọlọtọ, n'otu n'otu.
Isi njedebe nke ọmụmụ ihe ahụ bụ njedebe mgbagwoju anya nke ọnwụ obi obi ma ọ bụ ụlọ ọgwụ obi mgbawa mbụ;njedebe nke abụọ gụnyere akụkụ nke isi njedebe, nke mbụ na nke na-esote obi mgbawa ụlọ ọgwụ (ihe mbụ na nke na-emekarị), njedebe mgbagwoju anya nke ihe niile na-akpata ọnwụ ma ọ bụ obi mgbawa ụlọ ọgwụ, na ihe niile na-akpata ọnwụ.N'ihe na-esote ọnwa 10.8, enwere mbelata 10% na njedebe bụ isi nke ọnwụ obi ma ọ bụ ụlọ ọgwụ nkụda mmụọ mbụ na otu Vericiguat ma e jiri ya tụnyere placebo otu.